Stock comparison
Haemonetics
Medtronic
Scored across Buffett, Graham, Lynch and Greenblatt - plus a side-by-side metric table covering valuation, quality, growth and balance sheet.
HAE
Haemonetics
Market cap
$2.98B
Sector
Healthcare
MDT
Medtronic
Market cap
$100.91B
Sector
Healthcare
Overall winner
Haemonetics HAE
Wins on the combined sum of fit scores across all four strategies. Per-strategy breakdown below.
Fit scores by strategy
| Strategy | HAE | MDT | Winner |
|---|---|---|---|
| Warren Buffett | 70B | 58D | HAE |
| Benjamin Graham | 85A | 63C | HAE |
| Philip Fisher | 60C | 50C | HAE |
| Peter Lynch | 54C | 55C | MDT |
| Joel Greenblatt | 31F | 39D | MDT |
| Charlie Munger | 54D | 51D | HAE |
| Terry Smith | 55D | 52D | HAE |
Side-by-side metrics
| Metric | HAE | MDT |
|---|---|---|
| Market cap | $2.98B | $100.91B |
| P/E (TTM) | 24.8x | 21.2x |
| EV/EBIT | 14.1x | 20.9x |
| ROIC (TTM) | 8.37% | 6.43% |
| Gross margin | 55.74% | 61.95% |
| Net margin | 7.29% | 13.0% |
| Revenue CAGR 5y | 7.65% | 2.73% |
| EPS CAGR 5y | 24.62% | 7.88% |
| Debt / Equity | 1.5x | 0.6x |
| Dividend yield | 0.0% | 3.73% |
Where each one wins
The metrics with the biggest gap between the two - sorted so the most decisive edges read first.
HAE leads on
- EPS CAGR 5y24.62%vs 7.88%+68%
- Revenue CAGR 5y7.65%vs 2.73%+64%
- EV/EBIT14.1xvs 20.9x+33%
- ROIC (TTM)8.37%vs 6.43%+23%
MDT leads on
- Dividend yield3.73%vs 0.0%+100%
- Market cap$100.91Bvs $2.98B+97%
- Debt / Equity0.6xvs 1.5x+63%
- Net margin13.0%vs 7.29%+44%
Related on invest-like
Key terms in this analysis
Educational tool. Fit scores are deterministic projections from public financials onto each investor's published criteria - not personal recommendations or advice.